EPHA2 and cancer: Interestingly, a combined targeting of FAP+ CAFs and EPH receptor A2 (EphA2)+ cancer cells led to a nearly complete remission of the tumors (93), suggesting that CAF-targeted approaches have the potential to supplement and synergize with conventional cancer-cell-targeted therapies.